Medicines and medical consultations will be less reimbursed by Social Security in 2025, announces the Minister of Health

The Minister of Health and Access to Care, Geneviève Darrieussecq, at the podium of the National Assembly, October 28, 2024. JULIEN MUGUET FOR “THE WORLD”

In the middle of a budgetary debate in Parliament, the Minister of Health, Geneviève Darrieussecq announced Monday, November 18 that the reimbursement rate for medicines by Social Security will drop by 5% next year. This will also be the case for the payment of medical consultations, she added to the Senate.

Precisely, the “moderator ticket”most often the responsibility of complementary health insurance, “will only change by 5%” for medical consultations then “that it was potentially possible to increase it by 10%”more “in addition [celui] on medicines will increase by 5% »said the minister at the opening of debates in the Senate on the Social Security financing bill, although this measure could be taken by ministerial decree.

These refunds will result in a “transfer to complementary health insurance” whose amount “was reduced from 1.1 billion to 900 million euros” said M.me Darrieussecq.

Read also | Article reserved for our subscribers Social Security Budget: “A major collective failure”, deputies fail to vote within the deadline

Read later

A “skid” in drug spending in 2024

The government's initial project consisted of reducing the cost of medical consultations from 70% to 60%, which will therefore be reimbursed at 65% in the future. For medicines, the three existing reimbursement rates (65%, 30% and 15%) would a priori be lowered in the same proportion.

In addition, to achieve a savings objective “to the tune of 5 billion euros” on health spending, “we are also considering price reductions for health products amounting to 1.2 billion euros”as well as “efficiency measures at the hospital” for 600 million and also on city care for 600 million, added Mme Darrieussecq. Furthermore, the Minister of Health confirmed a “skid” drug expenses this year, “valued at 1.2 billion euros”which the government intends to limit after a “dialogue with manufacturers in order to find compensation mechanisms”.

Read also (2023): Article reserved for our subscribers Producing medicines in , a difficult health reconquest

Read later

The World with AFP

Reuse this content

France

-

-

PREV What does Joe Biden’s decision to allow Ukraine to use long-range US weapons mean?
NEXT Federal training: The new version of De Wever’s “super note” still does not appeal to Vooruit, the blockage continues